Cargando…
Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190569/ https://www.ncbi.nlm.nih.gov/pubmed/34112764 http://dx.doi.org/10.1038/s41392-021-00643-y |
| _version_ | 1783705711990013952 |
|---|---|
| author | Lin, ChangDong Li, Yue Zhang, YueBin Liu, ZhaoYuan Mu, Xia Gu, Chenjian Liu, Jing Li, Yutang Li, GuoHui Chen, JianFeng |
| author_facet | Lin, ChangDong Li, Yue Zhang, YueBin Liu, ZhaoYuan Mu, Xia Gu, Chenjian Liu, Jing Li, Yutang Li, GuoHui Chen, JianFeng |
| author_sort | Lin, ChangDong |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8190569 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-81905692021-06-10 Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction Lin, ChangDong Li, Yue Zhang, YueBin Liu, ZhaoYuan Mu, Xia Gu, Chenjian Liu, Jing Li, Yutang Li, GuoHui Chen, JianFeng Signal Transduct Target Ther Correction Nature Publishing Group UK 2021-06-10 /pmc/articles/PMC8190569/ /pubmed/34112764 http://dx.doi.org/10.1038/s41392-021-00643-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Lin, ChangDong Li, Yue Zhang, YueBin Liu, ZhaoYuan Mu, Xia Gu, Chenjian Liu, Jing Li, Yutang Li, GuoHui Chen, JianFeng Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction |
| title | Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction |
| title_full | Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction |
| title_fullStr | Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction |
| title_full_unstemmed | Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction |
| title_short | Correction To: Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein–ACE2 interaction |
| title_sort | correction to: ceftazidime is a potential drug to inhibit sars-cov-2 infection in vitro by blocking spike protein–ace2 interaction |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190569/ https://www.ncbi.nlm.nih.gov/pubmed/34112764 http://dx.doi.org/10.1038/s41392-021-00643-y |
| work_keys_str_mv | AT linchangdong correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT liyue correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT zhangyuebin correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT liuzhaoyuan correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT muxia correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT guchenjian correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT liujing correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT liyutang correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT liguohui correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction AT chenjianfeng correctiontoceftazidimeisapotentialdrugtoinhibitsarscov2infectioninvitrobyblockingspikeproteinace2interaction |